Anti–CTLA-4 therapy requires an Fc domain for efficacy

Ipilimumab, a monoclonal antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved “checkpoint”-blocking anticancer therapy. In mouse tumor models, the response to antibodies against CTLA-4 depends entirely on expression of the Fcγ receptor (FcγR), which may facilitate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Proc Natl Acad Sci U S A
Autors principals: Ingram, Jessica R., Blomberg, Olga S., Rashidian, Mohammad, Ali, Lestat, Garforth, Scott, Fedorov, Elena, Fedorov, Alexander A., Bonanno, Jeffrey B., Le Gall, Camille, Crowley, Stephanie, Espinosa, Camilo, Biary, Tamara, Keliher, Edmund J., Weissleder, Ralph, Almo, Steven C., Dougan, Stephanie K., Ploegh, Hidde L., Dougan, Michael
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2018
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5899492/
https://ncbi.nlm.nih.gov/pubmed/29581255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1801524115
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars